6 Citations (Scopus)

Abstract

Objective: The objective of the present study is to prepare a better form of paclitaxel cocrystal with improved solubility. Paclitaxel (PTX) is a class-4 drug; this drug has low aqueous solubility and high affinity for P-gp. Available formulation are IV based and using our research work with advantages of co-crystal technology towards the enhancement of paclitaxel solubility and thereby its bioavailability (1) and also to improve the patient compliance. Methods: Naringen was selected based on their chemical nature and its ability to inhibit P-gp, solvent assisted grinding method used to prepare the cocrystals, and prepared cocrystals were subjected to solid state characterization to determine the crystal structure of the cocrystals, as this can provide significant new insights into how the drug and coformer interact, and thereby provide an excellent crystal engineering guide to new cocrystals, potentially with improved properties. Instruments like Fourier transform infrared spectroscopy(FTIR), differential scanning calorimetry, X-ray powder diffraction will be used to determine their stability and any phase transformations (including decomposition) which they might undergo as a function of temperature. Results: Principle involved in the formation of cocrystal is hydrogen bonding between C=O and N-H group of drug and COOH groups of coformers, which is confirmed by FTIR data and DSC experiments were carried out to study the melting point and heat of enthalpy of the cocrystals. Results clearly shows that the melting point of the cocrystals was increased which confirms the formation of cocrystals. The drug and formation of cocrystals are explained by the X-ray powder diffraction patterns. The PXRD patterns of the pure drug showed sharp, well-defined peaks(spectrum attached) and cocrystals PXRD patterns shows that there is a significant difference in the entire diffraction pattern, changes in peak locations with respect to pure drug indicates a change in the arrangement of molecules, hence confirms the development of new crystalline phase. Conclusion: The results obtained from the above experiments clearly shows the formation of cocrystals with improved solubility.

Original languageEnglish
Pages (from-to)32-37
Number of pages6
JournalInternational Journal of Applied Pharmaceutics
Volume8
Issue number4
DOIs
Publication statusPublished - 2016

Fingerprint

Paclitaxel
Solubility
Pharmaceutical Preparations
Powder Diffraction
Fourier Transform Infrared Spectroscopy
X-Ray Diffraction
Freezing
Biomedical Enhancement
Aptitude
Differential Scanning Calorimetry
Hydrogen Bonding
Patient Compliance
Biological Availability
Hot Temperature
Temperature
Research

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

@article{e92f31dbef664637b87cda36ba524f59,
title = "Preparation, solid state characterisation of Paclitaxel and Naringen Cocrystals with improved solubility",
abstract = "Objective: The objective of the present study is to prepare a better form of paclitaxel cocrystal with improved solubility. Paclitaxel (PTX) is a class-4 drug; this drug has low aqueous solubility and high affinity for P-gp. Available formulation are IV based and using our research work with advantages of co-crystal technology towards the enhancement of paclitaxel solubility and thereby its bioavailability (1) and also to improve the patient compliance. Methods: Naringen was selected based on their chemical nature and its ability to inhibit P-gp, solvent assisted grinding method used to prepare the cocrystals, and prepared cocrystals were subjected to solid state characterization to determine the crystal structure of the cocrystals, as this can provide significant new insights into how the drug and coformer interact, and thereby provide an excellent crystal engineering guide to new cocrystals, potentially with improved properties. Instruments like Fourier transform infrared spectroscopy(FTIR), differential scanning calorimetry, X-ray powder diffraction will be used to determine their stability and any phase transformations (including decomposition) which they might undergo as a function of temperature. Results: Principle involved in the formation of cocrystal is hydrogen bonding between C=O and N-H group of drug and COOH groups of coformers, which is confirmed by FTIR data and DSC experiments were carried out to study the melting point and heat of enthalpy of the cocrystals. Results clearly shows that the melting point of the cocrystals was increased which confirms the formation of cocrystals. The drug and formation of cocrystals are explained by the X-ray powder diffraction patterns. The PXRD patterns of the pure drug showed sharp, well-defined peaks(spectrum attached) and cocrystals PXRD patterns shows that there is a significant difference in the entire diffraction pattern, changes in peak locations with respect to pure drug indicates a change in the arrangement of molecules, hence confirms the development of new crystalline phase. Conclusion: The results obtained from the above experiments clearly shows the formation of cocrystals with improved solubility.",
author = "Muddukrishna, {B. S.} and Dengale, {Swapnil J.} and Shenoy, {Gautham G.} and Krishnamurthy Bhat",
year = "2016",
doi = "10.22159/ijap.2016v8i4.14251",
language = "English",
volume = "8",
pages = "32--37",
journal = "International Journal of Applied Pharmaceutics",
issn = "0975-7058",
publisher = "International Journal of Applied Pharmaceutics",
number = "4",

}

TY - JOUR

T1 - Preparation, solid state characterisation of Paclitaxel and Naringen Cocrystals with improved solubility

AU - Muddukrishna, B. S.

AU - Dengale, Swapnil J.

AU - Shenoy, Gautham G.

AU - Bhat, Krishnamurthy

PY - 2016

Y1 - 2016

N2 - Objective: The objective of the present study is to prepare a better form of paclitaxel cocrystal with improved solubility. Paclitaxel (PTX) is a class-4 drug; this drug has low aqueous solubility and high affinity for P-gp. Available formulation are IV based and using our research work with advantages of co-crystal technology towards the enhancement of paclitaxel solubility and thereby its bioavailability (1) and also to improve the patient compliance. Methods: Naringen was selected based on their chemical nature and its ability to inhibit P-gp, solvent assisted grinding method used to prepare the cocrystals, and prepared cocrystals were subjected to solid state characterization to determine the crystal structure of the cocrystals, as this can provide significant new insights into how the drug and coformer interact, and thereby provide an excellent crystal engineering guide to new cocrystals, potentially with improved properties. Instruments like Fourier transform infrared spectroscopy(FTIR), differential scanning calorimetry, X-ray powder diffraction will be used to determine their stability and any phase transformations (including decomposition) which they might undergo as a function of temperature. Results: Principle involved in the formation of cocrystal is hydrogen bonding between C=O and N-H group of drug and COOH groups of coformers, which is confirmed by FTIR data and DSC experiments were carried out to study the melting point and heat of enthalpy of the cocrystals. Results clearly shows that the melting point of the cocrystals was increased which confirms the formation of cocrystals. The drug and formation of cocrystals are explained by the X-ray powder diffraction patterns. The PXRD patterns of the pure drug showed sharp, well-defined peaks(spectrum attached) and cocrystals PXRD patterns shows that there is a significant difference in the entire diffraction pattern, changes in peak locations with respect to pure drug indicates a change in the arrangement of molecules, hence confirms the development of new crystalline phase. Conclusion: The results obtained from the above experiments clearly shows the formation of cocrystals with improved solubility.

AB - Objective: The objective of the present study is to prepare a better form of paclitaxel cocrystal with improved solubility. Paclitaxel (PTX) is a class-4 drug; this drug has low aqueous solubility and high affinity for P-gp. Available formulation are IV based and using our research work with advantages of co-crystal technology towards the enhancement of paclitaxel solubility and thereby its bioavailability (1) and also to improve the patient compliance. Methods: Naringen was selected based on their chemical nature and its ability to inhibit P-gp, solvent assisted grinding method used to prepare the cocrystals, and prepared cocrystals were subjected to solid state characterization to determine the crystal structure of the cocrystals, as this can provide significant new insights into how the drug and coformer interact, and thereby provide an excellent crystal engineering guide to new cocrystals, potentially with improved properties. Instruments like Fourier transform infrared spectroscopy(FTIR), differential scanning calorimetry, X-ray powder diffraction will be used to determine their stability and any phase transformations (including decomposition) which they might undergo as a function of temperature. Results: Principle involved in the formation of cocrystal is hydrogen bonding between C=O and N-H group of drug and COOH groups of coformers, which is confirmed by FTIR data and DSC experiments were carried out to study the melting point and heat of enthalpy of the cocrystals. Results clearly shows that the melting point of the cocrystals was increased which confirms the formation of cocrystals. The drug and formation of cocrystals are explained by the X-ray powder diffraction patterns. The PXRD patterns of the pure drug showed sharp, well-defined peaks(spectrum attached) and cocrystals PXRD patterns shows that there is a significant difference in the entire diffraction pattern, changes in peak locations with respect to pure drug indicates a change in the arrangement of molecules, hence confirms the development of new crystalline phase. Conclusion: The results obtained from the above experiments clearly shows the formation of cocrystals with improved solubility.

UR - http://www.scopus.com/inward/record.url?scp=84990049901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990049901&partnerID=8YFLogxK

U2 - 10.22159/ijap.2016v8i4.14251

DO - 10.22159/ijap.2016v8i4.14251

M3 - Article

VL - 8

SP - 32

EP - 37

JO - International Journal of Applied Pharmaceutics

JF - International Journal of Applied Pharmaceutics

SN - 0975-7058

IS - 4

ER -